CDK4/6 inhibitors for hormone-resistant breast cancer (2015-2017)
Palbociclib, ribociclib, and abemaciclib were approved after trials showed that adding a CDK4/6 inhibitor to hormone therapy extended progression-free survival in advanced breast cancer patients whose tumors had developed resistance.
Combination therapy became the standard of care for metastatic HR-positive, HER2-negative breast cancer.
Demonstrated that blocking the specific pathways resistance mechanisms rely on can meaningfully extend survival.
Shows the path from preclinical discovery to clinical standard of care when a second drug targets the resistance mechanism directly.
